CP-461 in the Treatment of Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in
patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of
CP-461 in this patient population.